Regulatory Framework Overview
The governing legislation
Singapore regulates medical devices under two instruments:
The Health Products Act (Cap. 122D) (HPA) is the primary legislation. It establishes HSA's powers to regulate health products (including medical devices), sets out the offence and penalty framework, and defines the scope of regulated activities. The Act was first enacted in 2007 and has been amended several times since.
The Health Products (Medical Devices) Regulations 2010 (HP(MD) Regulations) is the principal subsidiary legislation. It provides the operational detail for medical device regulation — classification rules, registration requirements, dealer's licensing, adverse event reporting, and FSCA obligations.
Both instruments are administered by the Health Sciences Authority (HSA), a statutory board under the Ministry of Health.
The Health Sciences Authority (HSA)
HSA is Singapore's national regulatory authority for health products. For medical devices, HSA's Health Products Regulation Group (HPRG) is responsible for:
- Setting and enforcing regulatory requirements for medical devices;
- Evaluating and approving product registration applications;
- Issuing and maintaining dealer's licences;
- Monitoring post-market safety and compliance;
- Liaising with international regulatory bodies (IMDRF, ASEAN AMDC, WHO).
HSA's medical device functions are accessible at hsa.gov.sg/medical-devices.
The SHARE portal
All regulatory transactions with HSA for medical devices — product registration, product notifications (Class A), dealer's licence applications, adverse event reports, and change notifications — are conducted through the SHARE (Submission of Health products And Registration via E-portal) online portal.
SHARE replaced the legacy PRISM portal. References to PRISM in older HSA guidance documents or company SOPs should be understood as referring to SHARE.
The dual obligation model
The most important structural feature of Singapore's framework is that two separate and parallel obligations apply to anyone supplying medical devices in Singapore:
-
Product registration (or Class A notification): the device must be on the Singapore Medical Device Register (SMDR) before it can be supplied. Registration is held by the registrant — a Singapore-registered entity.
-
Dealer's licence: the entity that manufactures, imports, or wholesales the device must hold a valid dealer's licence. The licence is specific to the type of activity and must be in place before any regulated dealing commences.
These obligations are independent. The registrant and the licensed dealer may be the same company or different companies, but both requirements must be met. See The Dual Obligation Model and Dealer's Licence — Overview for full details.
What the framework requires — at a glance
| Activity | Requirement |
|---|---|
| Classifying a device | Determine Class A, B, C, or D using the HP(MD) Regulations classification rules |
| Class A device | Product notification via SHARE (no registration fee, but notification required) |
| Class B, C, or D device | Product registration via SHARE under the applicable evaluation route |
| Manufacturing in Singapore | Manufacturer's dealer's licence |
| Importing into Singapore | Importer's dealer's licence |
| Wholesaling in Singapore | Wholesaler's dealer's licence |
| Change to a registered device | Change notification to HSA before implementation |
| Adverse event | Mandatory reporting to HSA within prescribed timeframes |
| Field Safety Corrective Action | Mandatory reporting and field action notification |
| Advertising a medical device | Compliance with HSA advertising guidelines |
How the framework relates to other jurisdictions
Singapore's framework was developed with reference to international best practice, particularly the Global Harmonization Task Force (GHTF) and its successor, the International Medical Device Regulators Forum (IMDRF). Singapore is a founding member of IMDRF.
The classification system (A/B/C/D) is broadly aligned with the GHTF/IMDRF risk-based approach. The evaluation route system (Full, Abridged, Expedited, Immediate) formally recognises approvals from five overseas reference agencies — TGA (Australia), EU Notified Bodies, Health Canada, MHLW (Japan), and US FDA — as the basis for streamlined review.
Singapore is also an active participant in the ASEAN Medical Device Committee (AMDC) and the ASEAN harmonisation programme. See International & ASEAN.